Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: Potential mechanisms of action

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 469-475

  Mitchell, I J ^a   Carroll, C B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

(R) HA 966; Excitatory amino acid; Globus pallidus; Glutamate; Glycine; Kappa opiate; NMDA; Parkinsonism; Polyamine ifenprodil; Primate; Striatum

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; AMINO ACID RECEPTOR BLOCKING AGENT; IFENPRODIL; KAPPA OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ARTICLE; ATAXIA; CORPUS STRIATUM; DRUG MECHANISM; GLOBUS PALLIDUS; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; PARKINSON DISEASE, SECONDARY; PRIMATES;

EID: 0030990697     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00036-X     Document Type: Article

References (63)

1. 1. Albin, R. L.; Young, A. B.; Penney, J. B., The functional anatomy of basal ganglia disorders. Trends in Neurosciences, 12, 366-375 1989.
2. 2. Augood, S. J.; Emson, P. C. et al., Cellular localisation of enkephalin gene expression in MPTP-treated cynomologous monkeys. Molecular Brain Research, 6, 85-92 1989.
3. 3. Benazzouz, A.; Gross, C.; Feger, J.; Boraud, T.; Biolac, B., Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Pharmacol., 5, 382-389 1993.
4. 4. Bergman, H.; Wichmann, T.; Delong, M. R., Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-1438 1990.
5. 5. Bjorklund, A.; Lindvall, O.; Isacson, O.; Brudin, P.; Wictorin, K.; Streker, R. E.; Clarke, D. J.; Dunnett, S. B., Mechanisms of action of intracerebral neural transplants: studies on nigral and striatal grafts to the lesioned striatum. Trends in Neurological Sciences, 10, 509-516 1987.
6. 6. Brotchie, J. M.; Mitchell, I. J.; Sambrook, M. A.; Crossman, A. R., Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disoders, 6 (2), 133-138 1991.
7. 7. Buller, A. L.; Morrisett, R. A.; Monaghan, D. T. The NR2 subunit contributes to the pharmacological diversity of native NMDA receptors. Soc. Neurosci. Abstr., 19(2): 1356, 557.10; 1993.
8. 8. Carlsson, M.; Carlsson, A., The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. Journal of Neural Transmission, 75, 221-226 1989.
9. 9. Carlsson, M.; Carlsson, A., Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. Journal of Neural Transmission, 77, 65-71 1989.
10. 10. Carroll, C. B.; Holloway, V.; Brotchie, J. M.; Mitchell, I. J., Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology, 119, 55-65 1995.
11. 11. Close, S. P.; Elliott, P. J. et al., Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology, 102, 295-300 1990.
12. 12. Collingridge, G. L.; Bliss, T. V. P., NMDA receptors-their role in long-term potentiation. Trends in Neurosciences, 10 (7), 288-293 1987.
13. 13. Collingridge, G. L.; Singer, W., Excitatory amino acid receptors and synaptic plasticity. Trends in Pharmacological Sciences, 11, 290-296 1990.
14. 14. Crossman, A. R.; Peggs, D. et al., Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology, 28 (11), 1271-1273 1989.
15. 15. Domino, E. F.; Sheng, J., NMDA antagonist and dopamine D-1 and D-2 agonist interactions in MPTP-induced hemiparkinsonian monkeys. Journal of Pharmacological and Experimental Therapy, 264, 221-225 1993.
16. 16. Foster, A. C.; Kemp, J. A., HA-966 antagonizes N-methyl-D-aspartate receptors through a selective interaction with the glycine modulatory site. Journal of Neuroscience, 9 (6), 2191-2196 1989.
17. 17. Frayne, S. E.; Mitchell, I. J. et al., Distribution of enkephalin gene expression in the striatum of the parkinsonian primate: implications for dopamine agonist-induced dystonia. Molecular Neuropharmacology, 1, 53-58 1991.
18. 18. Gerfen, C. R.; McGinty, J. F.; Young, W. S., Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. Journal of Neuroscience, 11 (4), 1016-1031 1991.
19. 19. Graham, W. C.; Robertson, R. G.; Sambrook, M. A.; Crossman, A. R. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sciences 47: PL-91-PL-N97; 1990.
20. 20. Grimwood, S.; Wilde, G. J. C.; Foster, A. C., Interactions between the glutamate and glycine recognition sites of the N-methyl-D-aspartate receptor from rat brain,as revealed from radioligand binding studies. Journal of Neurochemistry, 60, 1729-1738 1993.
21. 3H]L-689,560 binding to the glycine site of the NMDA receptor from rat brain. European Journal of Pharmacology, 266, 43-50 1994.
22. 22. Hattori, H.; Wasterlain, C. G., Excitatory amino acids in the developing brain: ontogeny, plasticity, and excitotoxicity. Pediatric Neurology, 6, 219-228 1990.
23. 23. Ishii, T.; Moriyoshi, K. et al., Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. Journal of Biological Chemistry, 268 (4), 2836-2842 1993.
24. 24. Jiang, H.-K.; McGinty, J. F.; Hong, J. S., Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Research, 507, 57-64 1990.
25. 25. Kleckner, N. W.; Dingledine, R., Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science, 241, 835-836 1988.
26. 26. Klockgether, T.; Turski, L. et al., The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Annals of Neurology, 30, 717-723 1991.
27. 27. Kretschmer, B. D.; Winterscheid, B.; Danysz, W.; Schmidt, W. J., Glycine site antagonists abolish D2 but not D1 receptor mediated catalepsy in rats. Journal of Neural Transmission, 95, 123-136 1992.
28. 28. Kutsuwada, T.; Kashiwabuchi, N.; Mori, H. et al., Molecular diversity of the NMDA receptor channel. Nature, 358, 36-41 1992.
29. 29. Laitinen, L. V.; Bergenheim, A. T.; Hariz, M. I., Leksell's poster-oventral pallidotomy in the treatment of Parkinson's disease. Journal of Neurosurgery, 76, 53-61 1992.
30. 30. Landwehrmeyer, G. B.; Standaert, D. G.; Testa, C. M.; Penney, J. B.; Young, A. B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. Journal of Neuroscience, 15(7 Pt 2):5297-5307; 1995.
31. 31. Luquin, M. R.; Obeso, J. A. et al., The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. European Journal of Pharmacology, 235, 297-300 1993.
32. 32. Maneuf, Y.; Mitchell, I. J.; Crossman, A. R.; Woodruff, G. N.; Brotchie, J. M., Functional implications of kappa opiate receptor mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research, 683, 102-108 1995.
33. 3H-TCP-labeled receptors in rat brain. Journal of Neuroscience, 8, 493-501 1988.
34. 3H]MK-801 binding and reversal by glycine. Neuroscience Letters, 132, 73-76 1991.
35. 35. Miller, W. C.; Delong, M. R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter, M. B.; Jayaraman A., eds. Advances in behavioral biology, 32. The basal ganglia II. Structure and function-current concepts. New York: Plenum Press; 1987:395-403.
36. 36. Mitchell, I. J.; Clarke, C. E. et al., Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 32, 213-226 1989.
37. 37. Mitchell, I. J.; Hughes, N.; Carroll, C. B.; Brotchie, J. M. B., Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of EAA and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behavioral Pharmacology, 6, 492-508 1995.
38. 38. Mitchell, I. J.; Brotchie, J. M.; Cooper, A. J.; Crossman, A. R., Reversal of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in the primate. European Journal of Neuroscience, 4 (suppl.), 4050 1990.
39. 39. Monaghan, D. T.; Olverman, H. J.; Nguyen, L.; Watkins, J. C.; Cotman, C. W., Two classes of N-methyl-D-aspartate recognition sites: differential distribution and differential regulation by glycine. Proceedings of the National Academy of Sciences USA, 85, 9836-9840 1988.
40. 3H]-801 binding to subpopulations of NMDA receptors. Neuroscience Letters, 122, 21-24 1991.
41. 41. Monaghan, D. T.; Clark, H. C.; Schneider, B. E. Distributions of NMDA receptor subtypes correspond to specific receptor subunits. Soc. Neurosci. Abstr., 19(2): 1356, 557.9; 1993.
42. 42. Montastruc, J. L.; Rascol, O. et al., A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 85 (7), 630-631 1992.
43. 43. Monyer, H.; Sprengel, R. et al., Heteromeric NMDA receptors: molecular and functional distribution of subtypes. Science, 256, 1217-1221 1992.
44. 44. Moriyoshi, K.; Masu, M. et al., Molecular cloning and characterization of the rat NMDA receptor. Nature, 354, 774-776 1991.
45. 45. Morris, R. G. M.; Anderson, E.; Lynch, G. S.; Baudry, M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP-5. Nature, 319, 774-776 1986.
46. 46. Nakanishi, N.; Axel, R.; Schneider, N. A., Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors. Proceedings of the National Academy of Sciences USA, 89, 8552-8556 1992.
47. 47. Palombo, E.; Perrino, L. J.; Bankiewski, K. S. et al., Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracerebral infusion of the neurotoxin MPTP. Journal of Neuroscience, 10 (3), 860-869 1990.
48. 48. Parada, J.; Czuczwar, S. J.; Turski, W. A., NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil. Cognitive Brain Research, 1, 67-71 1992.
49. 49. Pollack, A. E.; Wooten, G. F., Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors. Molecular Brain Research, 12, 111-119 1992.
50. 50. Pullan, L. M.; Verticelli, A. M.; Paschetto, K. A., Agonist-like character of the (R)-enantiomer of 1-hydroxy-3-amino-pyrroli-2-one (HA-966). European Journal of Pharmacology, 208, 25-29 1991.
51. 51. Reynolds, I. J., Minireview: modulation of NMDA receptor responsiveness by neurotransmitters, drugs and chemical modification. Life Sciences, 47, 1785-1792 1990.
52. 52. Reynolds, R. J.; Miller, R. J., Allosteric modulation of NMDA receptors. Advances in Pharmacology, 21, 101-126 1990.
53. 53. Rothman, S. M.; Olney, J. W., Excitotoxicity and the NMDA receptor. Trends in Neurosciences, 10 (7), 299-302 1987.
54. 54. Rupniak, N. M.; Boyce, S.; Tye, S.; Cook, G.; Iversen, S. D., Anxiolytic-like and antinociceptive effects of MK-801 accompanied by sedation and ataxia in primates. Pharmacology and Biochemistry of Behavior, 44 (1), 153-156 1993.
55. 55. Scatton, B., The NMDA receptor complex. Fundamentals of Clinical Pharmacology, 7, 389-400 1993.
56. 56. Standaert, D. G.; Testa, C. M.; Young, A. B.; Penney, J. B., Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. Journal of Comparative Neurology, 343, 1-16 1994.
57. 57. Sugihara, H.; Moriyoshi, K. Structure and properties of seven isoforms of the NMDA receptor generated by alternative splicing. Biochemical and Biophysical Research Communications 185(3): 826-832.6; 1992.
58. 58. Uematsu, D.; Greenberg, J. H. et al., Mechanism underlying protective effect of MK-801 against NMDA-stimulated neuronal injury in vivo. Journal of Cerebral Blood Flow and Metabolism, 11, 779-785 1991.
59. 59. Wichmann, T.; Bergman, H.; DeLong, M. R., Increased neuronal activity in the subthalamic nucleus (STN) of MPTP treated monkeys. Movement Disorders, 5, 78 1990.
60. 60. Williams, K.; Russell, S. L. et al., Developmental switch in the expression of NMDA receptors occurs in vivo and in vitro. Neuron, 10, 267-278 1993.
61. 61. Wullner, U.; Kupsh, A.; Arnold, G.; Renner, P.; Scheid, C.; Scheid, R.; Oertel, W.; Klockgether, T., The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 31, 713-715 1992.
62. 62. Yamazaki, M.; Mori, H. et al., Cloning, expression and modulation of a mouse NMDA receptor subunit. FEBS, 300, 39-45 1992.
63. 3H]glutamate binding in primate brain. Journal of Neuroscience Research, 27 (4), 512-521 1990.